DBV Technologies Shares Stumble to €3.36 After Widened Quarterly Loss
The stock of the French biotech company declined sharply during the session to €3.36, following the announcement of its first quarter 2026 results last Thursday. The movement is part of a slightly bearish Parisian market, with the CAC 40 down by 0.46%. Year-over-year, the stock still shows a gain of 120.9%.
A Quarterly Loss Weighs on the Stock
DBV Technologies published its first quarter 2026 financial results on April 30. The net loss increased to $47.6 million, amid a significant rise in R&D expenses related to the progress of the Viaskin Peanut program. Concurrently, the company confirmed a cash reserve of $229 million as of March 31, which covers its needs until the second quarter of 2027 thanks to the full exercise of warrants issued during the private placement in March 2025. The regulatory timeline remains a central element of the case: the biotech plans two biologics license application submissions in 2026, one for the age group 4-7 years and the other for 1-3 years, as well as a new phase 2 study in infants aged 6 to 12 months.
Stock Price Approaches Lower Bollinger Band
At €3.36, the stock is nearing the lower Bollinger band set at €3.31, and is just above the support at €3.34. The RSI at 44 remains in the neutral zone, with no clear oversold signal despite today's drop. The price has fallen below the 50-day moving average (€3.60) but remains well above the 200-day moving average at €2.74, reflecting the strong increase accumulated over the past year. The next key date is the mixed general meeting on June 3, 2026, before the half-year results scheduled for July 29.
